Steward Health Care System

Return to Results

Raptiva Epidemiologic Study of Psoriasis Outcomes and Safety Events in Patients With Chronic Moderate to Severe Plaque Psoriasis (RESPONSE)

new search

Trial Conditions
  • Psoriasis
What is the purpose of this trial?

This was a multicenter, prospective, 5-year surveillance study of approximately 5000 Raptiva-treated patients and approximately 500 non-Raptiva treated patients (formerly 2500 comparison patients who were treated with a biologic therapy other than Raptiva) with chronic moderate to severe plaque psoriasis who were candidates for treatment with Raptiva.

Date & Status

Completed

Who can Participate?

Eligibility

Ages:
0 and older

Gender:
Both

Eligibility

Inclusion Criteria:

- Have ever had a physician's diagnosis of chronic moderate to severe plaque psoriasis
and be a candidate for treatment with Raptiva

- Are being treated with or initiating Raptiva therapy at the time of enrollment

- Be able to provide written informed consent

- Be willing and able to fully to participate for the duration of patient follow-up (5
years)

Exclusion Criterion:

- Have previously received at least one dose of Raptiva and are not currently using or
restarting treatment with Raptiva at the time of enrollment

Gender: Both
Steward Physician(s)
  • Ivor Caro, M.D.
Physician Researcher

Investigator Name:

  • Ivor Caro, M.D.

Other Information

Sponsor: Genentech
Phase: Phase 4
Trial ID: NCT00096928
Volunteers:  Not Accepting Healthy Volunteers

new search

Connect with Steward

Visit Our Twitter Feed Visit Our Facebook Page Email This Page Print This Page

Subscribe to our patient e-newsletter

Copyright © 2014 Steward Health Care
Connect Healthcare Panacea CMS Solutions